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lor example suggests that a positive National level (NICE) recommendation does 
not necessarily translate into common local prescribing behavior. Local variation 
(the fifth hurdle of market access) should be considered by pharmaceutical com-
panies when developing market access strategy.
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Objectives: Atherosclerotic cardiovascular diseases (CVD) remain the major cause 
of premature death in Europe. CVD treatment and precribing behavior remains 
a major challenge for the doctors, payers and regulatory bodies. Key aim of our 
study was to collect and compare reliable and comparable data on drug utiliza-
tion for CVD therapy in Slovakia during 8 years (2005-2012). MethOds: We uti-
lized review of available costs data sources connected to ATC classification and to 
cardiovascular diseases (C01-C10). We also looked for Daily Defined Doses (DDD) 
measurement units. We adopted time frame and data was consequently used for 
analysis. Costs were used in EUR. Results: Total increase in EUR spent on cardio-
vascular drugs was more than 60 million EUR (2012 vs 2005). Key growth drivers 
from selected ATC groups were Vasoprotectives and Calcium channel blockers with 
78% and 88% growth respectively (2012 vs. 2005). Amount of drug costs allocated 
for cardiovascular disease escalated in 2011 with almost 197 million EUR, average 
price for package reached 5,38 EUR in same year and price per 1 DDD was 0,17 EUR 
per 1 DDD (2012) compare to 0,16 EUR (2005). Overall unit sales results from 2005 to 
2012 show slide growth tendency till 2010 with following slight declined. Growth 
in units for all ATC group under our scope reached the level of 4,3% (2012 vs 2005). 
Standardized death rate for CVD decresed from 637,3 in 2005 to 510,4 in 2012 (per 
100.000). cOnclusiOns: Increase spending for CVD management translated also 
into decrease death rate (2012 vs 2005). It is important for regulatory bodies and 
payers to continue in taking adequate measures that will ensure rational pharmaco-
therapy alongside with improving prescribing behavior. Combining different meas-
ures, such as electronic prescription monitoring and promoting available guidelines 
for CVD management, could be an effective way.
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Objectives: According to National Cholesterol Education Program Adult Treatment 
Panel IV, lipid-lowing agent is required if in patient with atherosclerotic risks. The 
annual cost of statins consumption was the first five human medications in Taiwan. 
Therefore, disallowed/deduction of reimbursement from Administration of National 
Health Insurance (NHI) was relatively higher than other drugs. An “Automatic 
Laboratory data Checking System” was established in order to enhance rational 
use of statins and to reduce deduction rate of statins reimbursement. This study 
aims to analyze the economic outcomes after implemented the system. MethOds: 
The major cause of deduction was the lipid profile fragmented in the medical record. 
To ensure rational use of statins based on NHI regulation, an “Automatic Laboratory 
data Checking System” in computerized physician order entry (CPOE) system was 
implemented in a teaching hospital on February 2013. When processing a statin 
prescription through CPOE system, the prescriber should choose the lipid profile 
linked with laboratory system in our hospital, or filled in lipid profile performed at 
outside source. The prescription would be blocked if the inspection date and labora-
tory data were not adherence to the NHI regulation. Results: After system imple-
mentation, the deduction of statins reimbursement was significantly decreased. 
There were three indicators substantially improved in year 2013 than 2012: The 
average quarterly deduction was 2.16 million NTD reduced, the average quarterly 
deduction rate was 14% reduced (18.18% versus 3.95%), and the disallowed reim-
bursement account for 57.11% medication fee decreased to 7.17%. cOnclusiOns: 
The present study demonstrated that “Automatic Laboratory data Checking System” 
lessen the economic burden of statins reimbursement based on NHI regulations. 
The system was associated with rational use of statins and reducing disallowed 
reimbursement as well.
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Objectives: This real-world study evaluated the baseline characteristics of patients 
with non-valvular atrial fibrillation (NVAF) who had switched from warfarin to novel 
oral anticoagulants (NOACs). MethOds: Retrospective cohort study was conducted 
using the MarketScan® plus Earlyview data from 10/1/2009 to 12/31/2013. Adult 
NVAF patients (ICD-9 code 427.31 or 472.32) with one year of baseline period and 
a history of continuous warfarin use in the baseline period for at least 3 months 
immediately before the index date (defined as the first NOAC claim) were included. 
Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral 
stenosis, VTE, cardiac surgery, and endocarditis during the baseline period were 
excluded. Categorical variables were reported as percentages and frequencies, 
and continuous variables as means±SD. Categorical variables were compared 
using Pearson’s chi-squared test while continuous variables were compared using 
wilcoxon signed-rank test. Results: Among 11,743 eligible patients, 427 (3.64%) 
switched to apixaban, 8,989 (76.55%) to dabigatran and 2,327 (19.81%) to rivaroxaban. 
associated with NOAC use included rate/rhythm control treatments (OR: 0.78, 95% 
CI 0.73-0.83) and SSRI/SNRI antidepressants (OR: 0.87, 95% CI 0.79-0.96). Regional 
variation in initiation of NOACs versus warfarin was also observed. cOnclusiOns: 
Multiple comorbidities may be associated with lower likelihood of NOAC initiation, 
as recently observed in other jurisdictions. Such uptake patterns have implications 
for real-world cost-effectiveness and outcomes studies.
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Objectives: The objective of generic drugs policies can be defined as reduction in 
health care expenditure without compromising health outcomes. This definition 
is based on the disinvestment aspect of drug policies. However, the objective of 
generic drug policies can be also defined from an investment perspective, espe-
cially in those countries with volume limits for the use of original patented drugs 
due to economic constraints: increase in population health gain by improved 
patient access without need for additional health expenditure. Our objective was 
to compare benefits of generic drugs policies in Germany vs Hungary. MethOds: 
We reviewed the grey literature and IMS database to identify pharmaceutical prod-
ucts with (1) patent expiry in recent years, (2) major therapeutic advancement to 
previous standard therapies, (3) no direct therapeutic alternative at patent expiry, 
(4) pharmacy distribution and consequently reliable IMS sales records in differ-
ent countries. Then we compared aggregated annual volume sales in DOT and 
ex-factory sales for the selected pharmaceuticals in +/- 3 years before and after 
first generic entry. Results: In this analysis we present the case of clopidogrel. In 
Germany the volume sales of clopidogrel products increased by 1.7% with 3 years 
after first generic entry, in Hungary the increase was 120.5%. The ex-factory sales 
were reduced after patent expiry in both countries, by 30.1% in Germany and by 
59.5% in Hungary. cOnclusiOns: In Germany off-patent clopidogrel generated 
significant savings without volume increase. In Hungary generic products signifi-
cantly improved the accessibility of patients to clopidogrel therapy, in addition 
to reducing pharmaceutical expenditure. Incremental health gain of off-patent 
medicines should not be underestimated in those countries, where accessibility 
of patients to patented medicines in restricted.
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Objectives: From the total health care costs in Slovak Republic the costs of medi-
cines for treatment of cardiovascular diseases represent about 25%. In the world 
the proportion is at 8-10%. Accurate data on morbidity from cardiovascular disease 
in Slovak Republic is not available. National Health Information Center is process-
ing the data on prevalence and incidence of circulatory system diseases, but this 
includes only those patients who are followed in cardiology in SR. Reportedly, 
the prevalence of cardiovascular diseases in SR is about 250 000 patients (50.8/ 
1000 inhabitants). MethOds: The utilization of medicines in period from 2008 
to 2013 for treatment of cardiovascular diseases was analysed quantitatively by 
inderect descriptiv method of evaluating supply of medicines in quantitative units 
(number of packages), in the number of DDD and in financial indicators reflect-
ing the full value of consumed package. Data were gained from National Health 
Center and State Institute of Drug Control. Results: The decline of consumption 
expressed in number of packages was observed in the group of cardiac therapy 
and by peripheral vasodilatators. The groups of beta blocking agents, agents acting 
on the renin-angiotensin system and lipid modifying agents showed increase in 
consumption. In DDD units the consumption deacreased most significantly in the 
group of peripheral vasodilatators. Rise in DDD units was observed in the group 
of beta blocking agents, antihypertesives, beta blocking agents, agents acting on 
the renin-angiotensin system and lipid modifying agents. Atorvastatin was active 
agent with highest consumption in DDD. The highest average price per package was 
calculated by lipid modifying agents. After access of generic drugs to the market 
in 2008 the consumption in financial units declined while consumption in DDD 
grew in followed period. cOnclusiOns: By using the same amount of health care 
expenditures there is the possibility to provide treatment to more patients with 
cardiovascular disease.
PCV158
loCal Variation in PriMarY Care PresCribing behaVior in englanD: 
tiCagrelor
Sear R.D., Jenner H.D.
McKinsey & Co, London, UK
Objectives: To understand the level of local variation in community-level 
prescribing of ticagrelor in England, after national-level recommendation from 
NICE. MethOds: Monthly GP-Practice-level prescribing data was collected for 
antiplatelet drugs (Chapter 2.9 of British National Formulary [BNF]) in England, 
between August 2011 and February 2013. Data was obtained from the Health 
and Social Care Information Centre (HSCIC) and analyzed in Statistical Analysis 
Software (SAS). The percentage of total antiplatelet spend (net ingredient cost) 
attributed to ticagrelor was calculated for each GP Practice and Clinical com-
missioning Group (CCG) cluster. Results: Despite national-level NICE guid-
ance (December 2011) recommending the use of ticagrelor for Acute Coronary 
Syndrome, uptake of ticagrelor at CCG level varied greatly between August 2011 
and February 2013. The proportion of total antiplatelet spend on ticagrelor in 
February 2013 ranged from 0% to 34∙91%, between CCGs. The highest relative use of 
ticagrelor was clustered around the Yorkshire region. cOnclusiOns: The ticagre-
